光明与挑战:胶质瘤靶向治疗前沿进展  

Light and challenges:Advances in targeted therapy for glioma

作　　者：苏东元 康春生[1] SU Dongyuan;KANG Chunsheng(Tianjin Medi-cal University General Hospital,154 Anshan Road,Tianjin 300052,China;Lab of Neuro-oncology,Tianjin Neurological In-stitute,Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院,天津市神经病学研究所神经肿瘤研究室,天津300052

出　　处：《中国神经精神疾病杂志》2025年第1期1-7,共7页Chinese Journal of Nervous and Mental Diseases

基　　金：科技部重点研发计划(编号:2023YFC2510005)。

摘　　要：胶质瘤是成人最常见的恶性原发性脑肿瘤,特点是恶性进展迅速、复发率和致死率高。其主要治疗方式是手术和术后放、化疗。替莫唑胺作为胶质瘤临床治疗的一线化疗药,能有效改善患者预后,但其耐药问题却日益严峻。随着分子标志物检测水平的提高和精准医疗的提出,胶质瘤的靶向、个体化治疗策略也日新月异。胶质瘤新型标志物的发现,如:长链非编码RNA HOTAIR(HOX antisense intergenic RNA)、聚合酶Ⅰ和转录本释放因子(polymerase-1 and transcript release factor,PTRF/Cavin1)、MET等和计算机辅助药物设计(computer-aided drug design,CADD)等新技术的应用使得胶质瘤靶向药物的设计和研发进入一个新篇章。由于胶质瘤的异质性,单一靶向药物作用有限,在未来,物理、化学和生物等干预措施的结合才是胶质瘤治疗的突破方向。Glioma is the most common malignant primary brain tumor in adults,characterized by rapid malignant progression,high recurrence rates,and high mortality.The main treatment methods are surgery followed by radiotherapy and chemotherapy.Temozolomide,as the first-line drug for glioma treatment,is exposed to increasingly severe issues with drug resistance,which significantly impacts the efficacy and prognosis for glioma patients.With advancements in molecular biomarker detection and the emergence of precision medicine,targeted and individualized treatment strategies for glioma patients are evolving rapidly.The discovery of new glioma biomarkers,such as long non-coding RNA HOTAIR(HOX antisense intergenic RNA),polymerase I and transcript release factor(PTRF/Cavin1),and MET,along with the application of new technologies like computer-aided drug design(CADD),has ushered in a new era for the design and development of targeted drugs for glioma.Due to the heterogeneity of glioma,the effectiveness of single-target drugs is limited.In the future,a combination of physical,chemical,and biological interventions will be the breakthrough direction for glioma treatment.

关 键 词：胶质瘤 靶向治疗 分子标志物 计算机辅助药物设计 PTRF/Cavin1 HOTAIR MET 

分 类 号：R651[医药卫生—外科学]